Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$169.58M+399.58%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Dube
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 497
- Beta
- 1.06
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.59
Financials
Revenue
$169.58M+399.6%Net Income
$-34.80MEBITDA
$-32.87MFree Cash Flow
$58.07M+2868.9%EPS (diluted)
$-0.37Shares Outstanding (diluted)
93.48M+152.8%Operating Expenses
$156.40MCash & Debt
$489.18MRevenue by Segment (annual)
$490.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $490.73M | $-25.55M | $-0.56 |
| 2024 | $233.18M | $-321.55M | $-4.08 |
| 2023 | $145.24M | $-111.40M | $-1.50 |
| 2022 | $109.46M | $-278.48M | $-4.37 |
| 2021 | $131.84M | $-180.09M | $-3.01 |
| 2020 | $198.32M | $-169.43M | $-3.56 |
| 2019 | $175.34M | $-146.43M | $-3.46 |
| 2018 | $164.25M | $-102.68M | $-2.54 |
| 2017 | $154.94M | $-59.73M | $-1.54 |
| 2016 | $133.59M | $-47.90M | $-1.29 |
| 2015 | $99.89M | $117.24M | $3.49 |
| 2014 | $28.20M | $-110.94M | $-4.43 |
| 2013 | $0.00 | $-33.82M | $-2.38 |
| 2012 | $0.00 | $-30.34M | $-284.40 |
Valuation
TVTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
118+18.01%Social Signal Score
Mentions (6)
- News (Marketaux)gurufocus.com·12d ago·Positive
TVTX Looks 57.0% Overvalued on GF Value™ On September 23, 2026, Travere [+293 characters]
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
Travere Therapeutics Announces Planned Chief Executive Officer Transition SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Ph…
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to …
View source ↗ - News (RSS)investing·45d ago·Neutral
Travere Therapeutics stock hits 52-week high at 66.35 USD
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
Travere Therapeutics: Valuation Suggests A Buy Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.
View source ↗ - Newsmarketbeat.com·49d ago·Neutral
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.03 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.37 vs $-0.13miss
- Mon, May 4$-0.39 vs $-0.30miss
- Thu, Feb 19$0.03 vs $0.03beat
- Thu, Oct 30$0.28 vs $-0.31beat
- Wed, Aug 6$-0.14 vs $-0.28beat
- Thu, May 1$-0.47 vs $-0.55beat
Estimates and results for TVTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TVTX officers and directors.
- Bought
- —
- Sold
- $67.5m
0 trades
47 trades
- Heerma Petersold
- Dube Eric Msold
- Dube Eric Msold
- Rote William E.sold
- Rote William E.sold
- Heerma Petersold
- Heerma Petersold
- Dube Eric Msold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TVTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.